Drug Profile
Research programme: antibacterials - BioRelix/Merck
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BioRelix; Merck & Co
- Developer BioRelix
- Class
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 07 Oct 2010 Preclinical trials in Bacterial infections in USA (unspecified route)